STAT

DECEMBER 13, 2022

lawmakers wrote Pfizer chief executive officer Albert Bourla that he should “back off” from plans to charge Americans up to $130 for the company’s Covid-19 vaccine, a move they described as “pure and deadly greed.” argued the planned price tag is nearly four times the current $30 price paid by the U.S.

Vaccines 98

Vaccines 98

PharmaShots

MAY 19, 2023

Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US Date: May 19, 2023 | Tags: Alimera, EyePoint Pharmaceuticals, Yutiq, Iluvien, chronic non-infectious uveitis, US, Pharma Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A Date: May 19, 2023 | Tags: Sobi, Efanesoctocog Alfa, (..)

Medical Schools 40

Medical Schools FDA Immunization Vaccines 40

PharmaShots

FEBRUARY 17, 2023

Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)

FDA 40

FDA Vaccines 40

European Pharmaceutical Review

MARCH 1, 2023

In a recent study, Massachusetts Institute of Technology (MIT) researchers developed a new purification method to cut the costs of manufacturing protein drugs. The researchers demonstrated their method with lysozyme, an enzyme whose crystallisation properties have been well studied, and insulin.

Vaccines 92

Vaccines 92

pharmaphorum

DECEMBER 23, 2022

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. Professional reception of the findings.

Immunization 52

Immunization Hospitals Vaccines 52

pharmaphorum

JANUARY 21, 2022

And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. There is no easy answer to the question of how to incentivise innovation without restricting access.

Insurance 52

Insurance Vaccines 52

pharmaphorum

JANUARY 31, 2023

With the recent rapid rollout of Covid-19 vaccines, many people have raised questions about whether adequate research was conducted on these vaccines before approval. Given the high price tags placed on many medications, it’s easy to understand why patients often feel that they are being taken advantage of.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines Communication 52